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ABSTRACT  
 
Selenium binding protein1 (SELENBP1) has been associated with several cancers. Its exact role was 
unknown. We show that SELENBP1 is a methanethiol oxidase (MTO), related to MTO of 
methylotrophic bacteria, converting methanethiol to H2O2, formaldehyde and H2S, an activity not 
known to exist in humans. Mutations in SELENBP1 were found in five patients with a cabbage-like 
smelling breath. Increased levels of methanethiol and dimethylsulfide are the main odorous 
compounds in their breath and responsible for the malodor. Increased urinary excretion of dimethyl-
sulfoxide is a diagnostic biomarker of MTO-deficiency. Patient fibroblasts showed reduced amounts 
of SELENBP1 protein and  deficient MTO enzymatic activity which could be restored by lentiviral-
mediated expression of the wild-type SELENBP1 gene. A knockout mouse line showed the same 
biochemical characteristics. Our data define a novel inborn error of metabolism caused by MTO-
deficiency leading to a malodor syndrome. MTO deficiency may be a frequent inborn error of 
metabolism.  
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INTRODUCTION 
 
Volatile sulfur-containing compounds hydrogen sulfide (H2S), methanethiol (MT, CH3-SH) and 
dimethylsulfide (DMS, CH3-S-CH3) have been identified as the main contributors of halitosis or bad 
breath 1. The origin of halitosis can be intra- or extra-oral 2-4. Intra-oral halitosis is the most common 
form usually caused by MT and H2S produced by Gram-negative bacteria located on the dorsum of the 
tongue or in gingival- and periodontal crevices. Extra-oral halitosis has an estimated prevalence of 0.5-
3% in the general population 2. Its origin is less well understood. Extra-oral bad smelling breath can be 
caused by conditions affecting the nose, sinuses, tonsils, and esophagus, but evidence indicates that in 
some patients the extra-oral halitosis is blood-borne 3. In blood-borne halitosis malodorant 
compounds, most commonly DMS, are carried to the lungs where they enter the breath 3. Mouth and 
nose breath DMS concentrations of these patients showed a five- to six-fold increase compared to 
controls 2. The cause for increased DMS levels in these patients is unknown. DMS is produced from 
MT by methylation. Both compounds result from the complex microbiome-mammalian co-
metabolism of volatile sulfur compounds (Figure 1) 5,6. Under physiological conditions MT has three 
sources in the human body 7,8: production from sulfur containing amino acids by intestinal bacteria; 
formation within intestinal cells by methylation of H2S by thiol S-methyltransferase; biosynthesis from 
methionine by the transamination pathway in human endogenous metabolism. Under pathological 
conditions, it has been found that increased levels of DMS can lead to high concentrations of 
dimethylsulfoxide (DMSO) and dimethylsulfone (DMSO2) 9. The enzymes involved in these conver-
sions are largely unknown and a contribution of the gut bacteria is expected 5,6. Interestingly cancer 
patients were found to produce MT and DMS as prominent volatile organic compounds 10,11. DMS is 
produced in significant amounts by lung- and liver cancer cell lines 10,12 and was found in lung tumor 
tissue13.  
Recently, a methanethiol oxidase (MTO) was purified from the Hyphomicrobium strain VS 14,15. The 
gene encoding this enzyme was identified and showed 26% homology at the protein level to the 
human SELENBP1 gene, encoding a protein possessing selenium binding properties but with unknown 
function 16-18. Reduced expression of the human gene has been found in several tumors, and a tumor 
suppressor function has been suggested 19-21. We hypothesized that mutations in SELENBP1 could be 
causative for extra-oral halitosis. We studied five patients with extra-oral halitosis caused by elevated 
levels of DMS in the blood. We identified SELENBP1 as the human MTO, catalyzing the conversion 
of MT into formaldehyde, H2S and hydrogen peroxide (H2O2). Mutations in SELENBP1 cause extra-
oral halitosis and define a novel inborn error of metabolism.  
RESULTS  
 
Extra-oral halitosis patients  
We studied five patients from three unrelated families with extra-oral halitosis with a cabbage-like 
odor (Figure 2A). The patients had high levels of DMS in their mouth- and nose breath. Known 
causes, such as intake of DMS containing food, use of sulfur-containing medication, lower gastro-
intestinal problems, known metabolic defects such as methionine adenosyltransferase deficiency and 
tyrosinemia were excluded. Family A is a German family of Turkish origin with two affected children 
(AII-2 and AII-3), family B is Portuguese with one affected child (BII-2), and family C is a Dutch 
family with two affected children (CII-1 and CII-2). The unifying clinical feature was the pungent 
malodor from the breath. Other clinical signs and symptoms of the patients differed considerably (for a 
full description see Supplementary Note). The two patients in the Dutch family are from a non-consan-
guineous marriage and the malodor was their only clinical symptom. The mother of patients CII-1 and 
CII-2 had some complaints of halitosis. The parents of the other patients were consanguineous. The 
female patient in family A had malodor as only symptom while her brother had a broader spectrum of 
clinical symptoms with neurological features. The Portuguese patient also had neurological sequelae.  
 
Breath and body fluid analyses 
Breath and body fluid analyses used complementary methods (NMR spectroscopy, gas-chromato-
graphy) (Table 1). Because of the malodor body fluid NMR spectroscopy was requested in the index 
patients of the three families. NMR showed the presence of increased concentrations of DMSO and 
DMSO2 in their body fluids (Figures 2 B and C). 
Using gas-chromatography with a sulfur detector an increased concentration of an additional sulfur-
containing compound, DMS, was detected (Table 1B). Increased DMS concentrations in blood have 
been described in patients with extra-oral halitosis 3,4. DMSO2 is an oxidation product of DMS. 
Increased DMSO2 concentrations have been observed in blood of patients with methionine 
adenosyltransferase deficiency 9. DMSO2 also occurs in cerebrospinal fluid after DMSO2 intake as 
dietary supplement 22. Additional investigations on breath samples of patients AII-3 and CII-2 
revealed increased levels of a fourth sulfur-containing compound, MT. The MT concentration in 
breath of these patients was ten times higher than the highest value in control persons and unaffected 
family members. Specialized dental clinics may use portable gas chromatography to detect this 
specific form of halitosis (see breath analysis of CII-2, Supplementary Figure 1). We detected 
increased MT levels in urine in some of our patient samples. Because MT is highly volatile and 
reactive, reproducible quantification of urinary MT was impossible.  
Patient BII-2 was treated for five days with the antibiotic Metronidazol (500 mg oral; three times/ 
day). The concentration of  DMS in breath decreased to just above the detection limit. DMS and MT 
in urine decreased to 65% after 5 days of Metronidazol. After cessation, the DMS levels in breath and 
urine returned to values before treatment. In patient AII-3 a methionine loading trial was performed. 
Initial levels of 18 and 129 μmol/mmol creatinine for DMSO and DMSO2 rose to 67 and 178, respec-
tively at 12 h after loading. At 20 h the levels were still increased (48 and 152). These data are in line 
with a significant contribution of the microbiome and as well of methionine metabolism to the breath- 
and body fluid concentration of MT, DMS and its further oxidation products DMSO and DMSO2 in 
the patients.  
 
Mutational analysis of SELENBP1 
Based on the profile of accumulating sulfur-containing compounds in our patients we postulated a 
defect in a pathway that would result in the accumulation of DMS. We hypothesized that defects in 
MT-oxidation would lead to increased levels of MT and lead to an alternative metabolism resulting in 
increased DMS, DMSO, and DMSO2 (Figure 1). MT degrading enzymes are not known in humans, 
but methanethiol oxidases (EC 1.8.3.4.) have been purified from Hyphomicrobium strain EG 23 and 
Thiobacillus thioparus TK-m 24. Recently a gene, mtoX, was found in Hyphomicrobium strain VS 
encoding a protein with MTO activity 15. BLAST searches of the human protein database using the 
Hyphomicrobium strain VS MTO amino acid sequence yielded a single hit, selenium-binding protein 1 
(SELENBP1/SBP1/hSBP/SBP56), with a sequence identity of 26% and homology of 54% 
(Supplementary Figure 2). The gene encoding this candidate protein, SELENBP1 is located on 
chromosome 1 (151.364.302-151.372.734), and lies within a linkage interval with a LOD-score of 1.8 
found in family A. The protein is well conserved in the three domains of life from human to bacteria 
and archaea (Figure 3A). Subsequent SELENBP1 Sanger sequencing showed 4 different bi-allelic 
mutations in our 5 patients (Table 2). Segregation with the malodour was confirmed in the three 
pedigrees. 
 
Pathogenicity of SELENBP1 mutations 
The four mutations were predicted to be pathogenic by the algorithms Align GVGD, SIFT, 
MutationTaster, and PolyPhen-2 (Table 2). When calculated by the CADD tool, the mutations ranked 
in the top 1% of most deleterious mutations (C-score ≥ 20) or even in the top 0.1% (C-score ≥ 30) 
(Table 2). We have modeled the human SELENBP1 protein containing the two mutations of family C 
on the X-ray structure of the hypothetical selenium-binding protein from the archaeon Sulfolobus 
tokodaii (PDB ID: 2ECE) (Figure 3B and C). Gly225Trp is likely incompatible with the original 
structure since glycine-225, without side chain, is replaced by a bulky tryptophan. Moreover, Gly225 
is conserved in methanethiol oxidases and putative selenium binding proteins from all domains of life. 
For the c.985C>T mutation changing His329 to Tyr the pathogenicity is less obvious from the 
structure analysis. The mutant residue is only slightly larger and does not seem to collide with adjacent 
side chains but His329 is conserved in eukaryotic orthologues and is in close proximity to a fully 
conserved region (Figure 3D). 
 Diagnostic assay for MTO enzyme deficiency  
We have developed a functional MTO enzymatic assay to prove that SELENBP1 has MTO activity, to 
evaluate its biochemical characteristics and to establish the residual activity in patients (see Online 
Methods and Supplementary Figure 3. MTO activity in different blood fractions of control individuals 
revealed relatively high activity in erythrocyte extracts, but with a broad range (0.04 - 6.1 nmol.µl-1.h-
1, mean 1.4, median 0.63; n=30, Figure 4A, see Supplementary Data1 for full length blots of Figure 4). 
MTO activity was low in leucocytes from control individuals and hardly detectable in plasma (not 
shown). Erythrocytes of the patients AII-3 and CII-2 had very low MTO activity (0.017 and 0.022 
nmol.µl-1.h-1) in line with a deficiency of the enzyme and adding to the functional role of the 
SELENBP1 protein as a methanethiol oxidase. 
 
SELENBP1 protein and activity in cell lines 
SELENBP1 mRNA was found to be ubiquitously expressed. The highest RNA levels were found in 
adult tissues, mainly in kidney, duodenum, liver, lung, and the brain (Figure 4B). 
SELENBP1 has been described as a tumor marker with decreased expression in certain cancers and 
tumor cell lines 20,21. To correlate the protein expression levels with our biochemical assay we 
analyzed colon cancer lines with previously documented high (HT29 cells) and low SELENBP1 
expression (SW480 cells)  25. Western blot analysis of these cell lines (Figure 4C) was in agreement 
with published results. MTO enzymatic activity was high in HT29 cells (4.2 nmol.mg protein-1.h-1) and 
undetectable in SW480 cells, nicely in line with expression data from literature and corresponding 
with Western blot results. 
Fibroblast lines from patients (AII-3 and CII-2) had significantly lower SELENBP1 protein levels than 
control cells (Figure 4D). MTO enzyme activity in the patient cells was not detectable (controls: 2.6-
6.6 nmol.mg protein-1.h-1). We could demonstrate that the MTO enzyme activity in control fibroblasts 
is dependent on the presence of oxygen (data not shown) and that the molar amount of H2S formed 
equals the amount of converted substrate MT.  
 
SELENBP1 has a nanomolar range Km for MT 
For accurate kinetic analysis we supplemented the reaction mixture with 0.3 mg/ml of BSA, which 
stabilizes MTO at low protein concentrations. A kinetic analysis with erythrocytes was performed by 
varying the initial MT concentrations and measuring the initial reaction rates (Supplementary Figure 
3D), resulting in  a remarkably low apparent Km value of 4.8 nM. When using different cell and tissue 
sources of MTO we could measure the decrease of MT in the headspace of the reaction down to low 
nanomolar amounts (Supplementary Figure 3E-G). Curve fitting resulted in similar apparent Km values 
for all tested extracts. 
 
Frequency of SELENBP1 mutations 
Using data from the ExAC browser and a local dataset of 15,000 exomes we found evidence for a 
possible frequency of bi-allelic pathogenic SELENBP1 mutations of approximately 1 : 90,000 
corresponding to a carrier frequency of 1 per 300 individuals (See Supplementary Note, and 
Supplementary Table 1). Based on these data MTO deficiency may be a frequent inborn error of 
metabolism. The frequency of extra-oral halitosis has been estimated by Tangerman et al 2 to be 
between 0.25-1.5% indicating that bi-allelic mutations in SELENBP1 can explain a minority of extra-
oral halitosis cases. 
 
Lentiviral complementation analysis 
To further substantiate that the MTO activity depends on the presence of SELENBP1 we performed a 
lentiviral complementation experiment in a patient fibroblast cell line (Figure 4F). The cell line of 
patient AII-3 and a control fibroblast line were lentivirally transduced with either a control virus 
expressing V5 epitope tagged green fluorescent protein (GFP), or a virus expressing V5-tagged wild-
type SELENBP1. The exogenous protein was expressed partly in the nucleus but mostly in the 
cytoplasm. The cytoplasmic staining was not uniform but seemed to follow internal filamentous 
structures (Supplementary Figure 4). This confirms previous studies 21,26,27. 
Subsequently, we analyzed MTO activity in stably expressing cell lines. The MTO activity in patient 
fibroblasts expressing GFP protein only and the non-transduced cells was undetectable. In addition, 
little or no SELENBP1 protein was seen on Western blot. Introducing exogenous SELENBP1-V5 
protein in patient fibroblasts resulted in re-expression of SELENBP1, as detected with the specific 
antiserum as well as with an anti-V5 tag antiserum. Moreover, the MTO enzyme activity increased 
from undetectable to 55% of the control cell line.  
 
SELENBP1 knockout mouse 
A knockout mouse line was previously created by the Knockout Mouse Program Project (KOMP) at 
UC Davis. This mouse, expressing a “knockout (KO) first” allele of the Selenbp1tm1b(KOMP)Wtsi gene, 
had no apparent phenotypic changes. MTO enzyme activity and metabolite concentrations were 
measured in KO mice, heterozygous carriers and wild type mice. MTO activity in erythrocytes of wild 
type mice was 1.8 nmol.µl-1.h-1, which is in the same order of magnitude as found in human 
erythrocytes. MTO activity in mouse erythrocytes was also strictly dependent on oxygen and yielded 
stoichiometric amounts of sulfide (not shown). 
MTO activity in KO mice erythrocytes was deficient (on the limit of detection at 0.05 nmol.µl-1.h-1) 
while an intermediate activity was found in heterozygous mice (0.8 nmol.µl-1.h-1, Figure 5A). MTO 
enzyme activity was measured in four different tissues (Figure 5B). The highest activity in wild type 
animals was found in liver. Activity in liver and kidney was more than tenfold higher compared to 
muscle and brain. In KO animals the residual activity was <6% in all tissues compared to wild type 
animals illustrating the enzyme deficiency. The affinity constant of MTO from mouse tissue extracts 
(liver shown in Supplementary Figure 3G) and mouse erythrocytes (not shown) was 4-6 nM, similar to 
the low apparent Km in human erythrocytes and HT29 colon cells (Supplementary Figure 3E and F).  
Since the loss of MTO activity in the patients resulted in accumulation of DMS and DMSO2 we also 
measured these products in blood plasma of the mice. As MT is expected to be much lower than DMS 
in blood and because of the highly volatile nature of the compound, MT quantification was not 
undertaken in the small amounts of plasma available. DMS in plasma of KO mice was significantly 
increased over control levels (Figure 5C). Interestingly somewhat increased plasma DMS levels were 
also seen in the heterozygous mice. This implies a mild biochemical phenotype of the gene defect in 
the heterozygous mice illustrating that the reduced MTO activity cannot cope with the usual flux 
through this enzymatic reaction. There was an accumulation of DMSO2 in plasma in the KO mice that 
was not detectable in both the wild type mice (Figure 5D and E; 36 µM) and the heterozygous mice 
(not shown). Overall the biochemical characteristics of the patients were mimicked in the KO mouse 
model. 
  
DISCUSSION 
 
We describe a group of patients suffering from extra-oral halitosis. All known causes for extra-oral 
halitosis, fetor hepaticus caused by liver cirrhosis 28, medicine use, cysteamine treatment in cystinosis 
29, were excluded.  Also methionine adenosyltransferase deficiency 9,30 and trimethylaminuria 3 were 
excluded. Our patients have increased concentrations of four sulfur-containing metabolites in their 
body fluids and breath. MT and DMS have a high odor index and are responsible for their malodor. 
Increased urinary excretion of DMSO2  is characteristic and diagnostic for this form of extra-oral 
halitosis. MT is known to be produced in substantial amounts by gut bacteria. We hypothesized that 
the metabolic defect in our patients relates to an impairment of MT metabolism. It was known that MT 
is oxidized towards H2S 7 but the enzyme, a methanethiol oxidase, had never been found. Our data 
show that SELENBP1 is the long-sought human MT-oxidase.  
Bi-allelic mutations in SELENBP1 are the underlying cause for a novel autosomal recessive 
malodor syndrome. Mutations in SELENBP1 had never been implicated with a genetic disorder. 
Increased expression of SELENBP1 was found in blood and in dorsolateral prefrontal cortex of 
schizophrenia patients 31-33.  
 The malodor is the unifying clinical feature in our patients. It is the only clinical feature in 
both patients of family C. There is consanguinity in the families A and B. The additional neurological 
signs and symptoms of  patients AII-3 and BII-2 but not of AII-2 may have had other causes. Whole 
exome analysis in family A identified pathogenic mutations in THAP4 as a potential cause for the 
neurological features in AII-3 (see Supplementary Note, for detailed Patient Description and 
Supplementary Figure 5). Our data thus suggest that defects in SELENBP1 may cause a malodor 
syndrome without neurological sequelae. Further studies are required to unravel the full phenotypic 
consequences of SELENBP1 defects. Furne et al 34 have described a specialized detoxification system 
in colonic mucosa that converts MT to appreciable amounts of H2S. Defective mucosal detoxification 
of MT may lead to ulcerative colitis 34. They see a potential link with the strong familial clustering of 
ulcerative colitis. Based on our findings it may be worthwhile to investigate a potential involvement of 
SELENBP1 in ulcerative colitis.   
 
SELENBP1 was first cloned by Chang 35 based on homology to the mouse selenium binding protein 
(mSBP56) 17,18. Binding of selenite by SELENBP1 was suggested  to occur via cysteine-57 16. The 
bacterial MTOs do not have Cys at the 57-position nor in close proximity. Therefore Selenium binding 
seems not essential for MTO enzyme activity of SELENBP1. Selenite binding was found essential for 
a specific interaction of SELENBP1 with the von Hippel-Lindau protein-interacting deubiquitinating 
enzyme 1 26. SELENBP1 was not known to possess enzymatic activity 26. In incubations of control 
human fibroblasts and erythrocytes with the MTO-substrate MT we observed a rapid conversion of 
MT in time and were able to measure stoichiometric amounts of the H2S formed. The enzymatic acti-
vity was strictly dependent on the presence of oxygen. We based the presumed reaction formula (Figu-
re 1) on our results and on the homologous Hyphomicrobium strain VS enzyme for which also H2O2 
and formaldehyde were confirmed as reaction products. The apparent Km value of the human MTO 
towards MT, 4.8 nM, is very low. According to the BRENDA database there are only very few 
enzymes with such a low Km value. The formation of DMS from MT is normally of minor importance 
(an estimated 1% of MT is converted into DMS in control individuals 7). The high flux through the 
MTO reaction becomes apparent in our patients and in the KO mouse model. In the deficiency state an 
alternative metabolic pathway comes in place resulting in substantial amounts of DMS, DMSO and 
DMSO2 in the body fluids of the affected individuals. This underpins the relevance of the MTO enzy-
me reaction in human metabolism. 
 
Deficiency of MTO activity may have metabolic consequences. These can be toxicity effects due to 
accumulating sulfur compounds. Data on toxicity of MT, DMS and DMSO are anecdotal and only 
little is known about low-dose toxicity of these compounds (36, and TOXNET) . No cell biological 
effects of an increased MT concentration have been documented. The MTO enzymatic activity of the 
SELENBP1 protein sheds new light on this because at least two of the products of this enzyme, H2O2 
or H2S, are biologically active molecules possessing cellular signaling functions. Decreased 
availability of H2O2 or H2S may have metabolic consequences. H2O2 is important because of its role in 
cellular signaling 37. H2S is a gaseous signaling molecule, a gasotransmitter, like nitric oxide and 
carbon monoxide 38. At low concentrations it acts as mitochondrial electron donor thus stimulating 
electron transport in mammalian cells 5. The general effect of H2S is cyto-protective 5 and H2S therapy 
for several disorders aims at vasodilatation, antioxidant upregulation, inflammation inhibition, and 
activation of anti-apoptotic pathways 38-40. At high concentrations H2S is toxic by its known inhibition 
of the respiratory chain complex IV. In view of these literature data we cannot exclude that toxic 
effects of accumulating sulfur compounds or the lack of H2O2 or the gasotransmitter H2S may be 
causing other clinical signs and symptoms in patients with SELENBP1 mutations than malodour only. 
The low apparent Km of MTO may be important to avoid MT toxicity but also may have a role in the 
gasotransmitter producing system that operates at the nanomolar level. Three enzymes in human 
metabolism are known to produce H2S. These are cystathionine β-synthase (CBS), cystathionine γ-
lyase (CSE or CGL) and 3-mercapto-pyruvate sulfur transferase (3MST) 41. Our data show that the 
MTO encoded by SELENBP1 is a fourth human H2S producing enzyme. The degree to which 
SELENBP1 contributes to the total H2S production is so far unknown. 
One may speculate that the function of SELENBP1 may lie in keeping the breath MT concentration 
low enabling the human nose to detect foul smell from  environmental volatile sulfur compounds. The 
human nose is very sensitive for MT and DMS which have a very high odor index 3. The sensitivity 
towards sulfur-containing compounds is evolutionary beneficial since these compounds often 
represent ‘danger’ in the form of decaying food sources. The low apparent Km of MTO is essential to 
keep the MT concentration in the body below the odor threshold level.  
 
The presence of MTO activity in erythrocytes seems rather surprising since red blood cells have only 
few functions other than transporting oxygen. The presence of SELENBP1 protein as one of the major 
non-heme proteins in these cells has been described before in the naked mole rat 42 and in humans 33,43. 
Also one of the other known H2S producing enzymes, 3MST, has been found in erythrocytes. Local 
H2S production in the bloodstream may be important for vasodilatation 44,45. A second H2S producing 
enzyme in the red blood cell underpins the importance of this metabolite for this cell or the role that 
the erythrocyte plays in the delivery of H2S as cargo. It remains to be established which of these two 
enzymes has the most important contribution to H2S formation in the blood. We have no indications 
for vascular problems in patients with MTO mutations but this is open for further investigations. 
 
SELENBP1 is a possible biomarker for disease progression in several cancers, such as breast-, renal 
cell- and colorectal cancers and others 46. It is of note that we have no indication that patients with 
SELENBP1 mutations have an increased risk to develop cancer. Low SELENBP1 mRNA or protein 
levels are associated with a poor clinical cancer prognosis 46 suggesting that SELENBP1 might be a 
tumor suppressor 20. In line with a tumor suppressor role and the MTO enzymatic activity of 
SELENBP1 is the observation that A549 lung cancer- and the HepG2 liver cancer cell lines produce 
DMS and other volatile sulfur compounds 10,12,47. DMS and MT were found in breath of lung cancer 
patients 10,11. DMS, normally absent in lung tissue, was found in lung tumor tissue 13. MT was found 
increased in flatus samples of colon cancer patients 10. Interestingly prevention of diffusion of sulfur-
containing gases from the tumour in an animal model caused a significant decrease in tumour proli-
feration rate 11. The mechanism of SELENBP1 tumor suppression is largely unknown 25. The 
SELENBP1 interaction with the von Hippel-Lindau protein-interacting deubiquitinating enzyme 1, 
which is involved in cancer suppression may play a role 26. Also its interaction with GPX1 (gluta-
thione peroxidase 1), interestingly also a selenocysteine-containing protein, may be relevant 48. Both 
proteins are present in erythrocytes. GPX1 is a potent antioxidant enzyme involved in counteracting 
oxidative stress by reducing peroxide to water to limit its destructive effects 49. Several cancers have 
been described to have reduced GPX1 expression (reviewed by 50). Besides a tight physical inter-
action, SELENBP1 and GPX1 have complex regulatory effects on each other 48. Our finding that 
SELENBP1 is in fact a human MTO that produces H2O2, which is enzymatically converted by GPX1, 
may shed new light on the interactions between SELENBP1 and GPX1. Deregulation of either 
enzyme may cause a misbalance in local H2O2 concentrations. The H2O2 concentration must be 
controlled because of its bivalent roles in both oxidative damage as well as in cellular signaling 37. The 
function of SELENBP1 in sulfur metabolism sheds new light on the tumor suppression mechanism 
and the role of the local concentrations of MT, DMS and H2S in this process. It is well known that 
dogs can smell the presence of some tumors in patients 51. With our data it is tempting to speculate that 
MT and DMS are the compounds that the dogs will smell  in patients with cancer.  
Taken together the putative tumor suppression role of SELENBP1 and the presence of DMS in tumors 
nicely fit together against the background of the enzymatic function of SELENBP1 as the long sought 
methanethiol oxidase. 
 
In conclusion, our experiments have identified a novel human enzyme activity, a methanethiol oxi-
dase. The enzyme is encoded by SELENBP1. SELENBP1 mutations cause extra-oral halitosis, an 
autosomal recessive malodor syndrome that may occur frequently in the general population. 
Accumulating sulfur-containing metabolites cause the bad smell in the patients. Theoretically this 
syndrome may be a treatable inborn error of metabolism when using dietary measures. SELENBP1 
has been studied as a biomarker for several cancers. The finding that SELENBP1 has an enzymatic 
role in sulfur metabolism and influences the concentration of biologically active molecules as H2O2 
and H2S may provide new clues and targets for the cancer field.  
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TOXNET: https://toxnet.nlm.nih.gov/ 
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FIGURE LEGENDS  
 
Figure 1. Sulfur metabolism 
Diet, bacterial metabolism and endogenous metabolism contribute to the levels of MT, DMS, DMSO 
and DMSO2 and catabolites in the body. The main conversion of MT to H2O2, formaldehyde and H2S 
by the enzyme MTO (indicated by the cross) is deficient in the patients. The lower part shows the 
MTO reaction. All underlined metabolites have been confirmed in our assay. 
 
Figure 2. Extra-oral halitosis families 
Panel A, Schematic representation of the family trees of the affected families. Double horizontal line 
in families A and B indicate consanguineous marriages. Dark symbols represent affected individuals, 
crossed out symbols are deceased individuals. 
Panels B and C, One-dimensional 1H-NMR spectroscopy of human plasma measured at pH 2.50. 
Plasma from patient CII-2 (B) and a control sample (C). The spectra illustrate the increased 
concentration of DMSO2 in the patient. For quantitative data see Table 1B. 
 
Figure 3. Analysis of missense mutations in SELENBP1 
Panel A, Neighbor-Joining phylogenetic tree of methanethiol oxidases and putative selenium-binding 
proteins. The evolutionary distances were computed using the Dayhoff matrix based method and are in 
the units of the number of amino acid substitutions per site. Bootstrap values (500 replicates) are 
shown next to the branches for values > 60. Evolutionary analyses were conducted in MEGA6 52. 
Panel B, The SELENBP1 sequence was modeled on the X-ray structure of the hypothetical selenium-
binding protein from Sulfolobus tokodaii (PDB ID: 2ECE). The protein forms a typical WD40 fold. 
The positions of the mutations Gly225Trp (on the right) and His329Tyr (on the left) are indicated in 
red. 
Panel C, Detail of the amino acid changes that are found in family C. Green residue is the original, red 
the replacement in the patients. 
Panel D, Alignments of the regions of SELENBP1 of multiple species indicating the conserved 
residues found mutated in family C. The amino acid numbering is according to the human sequence. 
Asterisk indicates a fully conserved residue, colon indicates conservation between amino acids of 
strongly similar properties, period indicates conservation between amino acids of weakly similar 
properties. 
 
Figure 4. Analysis of SELENBP1 expression and MTO activity in human cell lines 
Panel A, MTO activity in human erythrocytes in control (n=30) versus  patients AII-3 and CII-2. Box 
indicates the median and the 25 - 75 percentile, whiskers indicate the minimal and maximal value. 
Panel B, SELENBP1 mRNA expression  in human fetal and adult tissues. Presented as fold change in 
comparison to the tissue with the lowest expression level. 
Panel C, Anti-SELENBP1 Western blot analysis in HT29 (high expression) and SW480 (low 
expression) colon cancer cell lines. Panel D, Western blot analysis of patient (CII-2 and AII-3) and 4 
control fibroblast cell lines. Upper panel: anti-SELENBP1. ▲, SELENBP1; , non-specific band. 
Lower panel: loading control (anti-actin). 
Panel E: Progress curve of MTO activity. ▲, control fibroblast C5120 ); ■, patient AII-3 ●,control 
incubation without protein added . At t = 0 MT was added to all samples; the arrow indicates a second 
addition of MT to the control fibroblasts when the substrate was depleted, resulting in restoration of 
the initial activity, indicating that the enzyme was still fully functional. 
Panel F: Lentiviral complementation of patient and control fibroblast using SELENBP1-V5 viruses 
shows restoration of the MTO activity. As a control GFP-V5 encoding viruses were used. Upper 
panel: Western blot analysis of SELENBP1 expression (anti-SELENBP1). Middle panel: Western blot 
analysis of the exogenous expressed V5 tagged proteins (closed arrowhead is SELENBP1-V5, open 
arrowhead is GFP-V5). Lower panel: loading control (anti-actin). 
In panels C, D and F the MTO activity of each sample is indicated below the lanes. BG = background, 
below 0.5 nmol.mg protein-1.h-1. 
 
Figure 5. MTO activity and DMS levels in SELENBP1 KO mice 
Panel A, MTO activity in erythrocyte extracts from SELENBP1 KO, heterozygous and wild type 
animals (n=7 for each group). MTO activity in erythrocytes of the SELENBP1 KO animals were at or 
under the level of detection.  
Panel B, MTO activities were determined in homogenates of mouse tissues of both SELENBP1 KO 
and  wild type animals (n=3 for each tissue and each genotype). Black symbols are plotted on the left 
Y-axis, open symbols on the right Y-axis. MTO activities in the muscle and brain of the SELENBP1 
KO animals were at or under the level of detection. 
Panel C, DMS levels in mouse plasma was determined from the SELENBP1 KO (n=5) as well as 
heterozygous (n=4) and wild type animals (n=3).  
For panels A, B and C, Boxes indicate the median and the 25 - 75 percentile, whiskers indicate the 
minimal and maximal values. Statistical analysis was performed with GraphPad Prism using a two-
sided unpaired t test with Welch's correction. ***, p<0.001; **, p<0.01; *, p<0.05.  
Panels D and E, Representative one-dimensional 1H-NMR spectroscopy of mouse plasma samples 
measured at pH 2.50. Plasma from a KO animal (D) and a wild type sample (E). The spectra illustrate 
the increased concentration of DMSO2 in the SELENBP1 knock out animals.  
  
TABLES 
 
Table 1 MT, DMS, DMSO and DMSO2 levels in patients. 
A 
 
MT  
(ppb) 
 DMS  
(ppb) 
 
Breath Ref. 0.05  +/- 0.05 
(range 0.01–0.24) 
6.1  +/- 4.5  
(range 1-19)  
AII-2 -  154/201  
 
AII-3 2.6  251/246/200  
 
BII-2 -  184  
 
CII-1 -  30/34  
  CII-2 2.3  40/67/104  
 
B 
 
DMS 
(nM) 
DMSO  
(µM) 
DMSO2  
(µM) 
Blood Ref. < 7  < 1  <1-24  
 
AII-2 192 - - 
 
AII-3 191/242 6 68 
 
BII-2 185 4 36 
 
CII-1 164 - - 
 
CII-2 156 - - 
CSF Ref. < 10  < 1  <1-25  
 
AII-3 104/114 8 112 
 
BII-2 - 8 41 
  
DMS  
(nM) 
DMSO  
(µmol/mmol Cr) 
DMSO2 
(µmol/mmol Cr) 
Urine Ref. <10  < 1  3-18  
 
AII-2 194 30 54 
 
AII-3 71-194** 31 47 
 
BII-2 265/480 10 60 
 
CII-1 - 4 31 
 
CII-2 - 4 28 
 
MT and DMS were measured using gas-chromatography and DMSO and DMSO2 were measured with 
NMR spectroscopy. Numbers separated by “/” are measurements on separate days. -, not determined . 
Panel A: MT and DMS levels measured in exhaled breath. Reference ranges were obtained from 20 
control persons sampled arbitrarily throughout the day (given as mean ± 1 SD and as well as range). 
The values from individual persons fluctuated during the day (up to a factor of 10), these values are all 
included in the reference range. The DMS reference range corresponds to the range previously 
published 2,53.  
Panel B: DMS, DMSO and DMSO2 levels in body fluids of the affected patients and controls. 
Reference ranges for DMSO2 have been described in Engelke et al 9. DMS was measured in blood, 
DMSO and DMSO2 in plasma.  **: range of measurements on different time points during the day. 
  
Table 2 Mutation analysis of SELENBP1 (NM_003944.3) 
 
Patient cDNA Genomic 
position 
GRCh37* 
Protein Prediction of pathogenicity C- score 
AII-2 and 
AII-3 
c.1039G>T 
homozygous 
g.151,338,044 p.Gly347* Premature stop codon 
 
  
38 
 
BII-2 c.481+1G>A 
homozygous 
g.151,340,674  Disruption of the 5’splice site of the intron following exon 5 28.7 
 
CII-1 and 
CII-2 
c.673G>T 
 
and 
 
 
c.985C>T 
 
g.151,338,921 p.Gly225Trp - Align GVGD: C15 (GV: 206.04 - GD: 178.95) 
- SIFT: Deleterious (score: 0, median: 3.57) 
- MutationTaster: disease causing (p-value: 1) 
- PolyPhen-2: Possibly damaging (HumDiv 1.0, HumVar 1.0) 
35 
 
g.151,338,098 p.His329Tyr - Align GVGD: C0 (GV: 227.83 - GD: 79.14) 
- SIFT: Deleterious (score: 0, median: 3.57) 
- MutationTaster: disease causing (p-value: 1) 
- PolyPhen-2: Possibly damaging (HumDiv 0.935, HumVar 
0.734) 
24.5 
 
 
 
ONLINE METHODS 
 
Patients and data 
This study adhered to the Declaration of Helsinki and written informed consent was obtained from 
each individual. Full description of the patients can be found in the Supplementary Note. 
 
Statistics, body fluids, cells and animal model 
Statistical analysis was performed using GraphPad Prism 5. 
Human blood cells were obtained from anonymized samples from the Radboud university medical 
center. White blood cells were obtained after dextran gradient sedimentation. The leucocyte fraction 
contained lymphocytes and granulocytes. Erythrocytes were obtained after slow centrifugation 
(600xg) of heparinized blood. Plasma and white blood cells were removed and the erythrocytes were 
extensively washed with PBS before being snap frozen as pellets. The erythrocyte extracts had a 
protein concentration between 240-280 mg/ml. Anonymized plasma was obtained from healthy 
volunteers after informed consent.  
The C57BL/6N- Selenbp1tm1b(KOMP)Wtsi/Mbp knockout mouse (Mus musculus) was genetically 
engineered to delete the critical coding region and create a homozygous null mutation of the Selenbp1 
gene in all somatic and germline tissues. This knockout model was generated as part of the U.S. 
National Institute of Health’s Knockout Mouse Production and Phenotyping Project. The knockout 
mouse line was created by the Knockout Mouse Program Project (KOMP) at UC Davis in full 
compliance with all applicable laws and regulations for the KOMP program. Animal care and use was 
conducted under guidelines provided by the 8th Revision of the Guide for the Care and Use of 
Laboratory Animals. The care, use, and disposition of all mice used in this study were reviewed and 
approved by the Institutional Animal Care and Use Committee of the University of California at 
Davis. This study used both male and female homozygous mutant  mice ranging in age from 8-18 
weeks of age for urine collections, and 11-20 weeks of age for end point blood and tissue collections. 
Mouse plasma samples, washed erythrocytes (as for the human erythrocytes) and snap frozen tissue 
samples were sent to Nijmegen in The Netherlands by courier and on dry ice. For the animal studies 
no randomization was used and no animals were excluded from this study. The investigators were not 
blinded to the group allocation of the animal samples. 
 
NMR spectroscopy of body fluids 
DMSO and DMSO2 in plasma, urine and cerebrospinal fluid (CSF) were measured using proton NMR 
spectroscopy essentially as described for plasma, CSF 9,54,55 and urine 56. The lower limit of detection 
for DMSO and DMSO2 amounts to 1 µM. 
 
GC analysis of H2S, MT and DMS 
Analysis of MT for comparison of fibroblast MTO activity was done with a Chrompack CP9001 GC 
that was equipped with a sulfur-specific flame photometric detector (FPD) and a two meter glass 
column (four mm ID) packed with Carbopack B HT, as described 57. In addition an Agilent 7890B gas 
chromatograph (Middelburg, The Netherlands) was used, of which the FPD detector had a lower 
detection limit (0.05 pmol). This allowed us to study the MT kinetics of MTO in the low nM range. 
This GC had the same column of Carbopak B HT100 fitted to the capillary inlet of the FPD detector 
(set at 200 °C). The empty part of the inlet side of the column was extended into the heated GC inlet 
(150 °C) up to the septum to avoid any contact of sample gas with metal parts, since MT and other 
volatile sulfur-containing compound are notorious for their stickiness to metals. For both GC's the 
carrier gas was nitrogen (80 ml/min). For MTO enzyme activity measurements where both hydrogen 
sulfide and MT were measured the column was set at 100 °C.  For higher sensitivity desired in MTO 
kinetics when sulfide was trapped, the temperature was set at 130 oC. For MT and DMS analysis in 
breath the initial column temperature was set at 100 °C and after 0.5 min. increased to 140 °C resulting 
in retention times of 0.6 min. for H2S, 1.4 min. for  MT and 6 min. for DMS, respectively.  
 
Analysis of MT and DMS in breath 
Breath samples were collected in three Liter Tedlar bags (SKC, Procare BV, Groningen, The Nether-
lands) via a tube (ID 4 mm). The end of this tube was pierced through a 12 mm rubber stopper. This 
stopper was pressed against one nostril while the other one was kept closed. The bag was filled in 2-4 
goes after a relative deep breath through the nose was taken. Each go took 5-10 seconds. For DMS 
analysis three ml subsamples were taken from the bag and injected into the GC (lower limit of 
detection: 1 ppb). For MT analysis 400 ml subsamples were concentrated on a Tenax tube (13 cm, 
3 mm ID) that was kept in dry ice (10 min. precooling). About 1.5 cm of the Tenax tube was sticking 
out above the dry ice pellets and insulated by polystyrene, to prevent MT absorbing at the very 
beginning of the Tenax. The breath subsamples were pushed manually over the Tenax tube with a 100 
ml glass syringe (with a Teflon plunger tip) at a rate of 5 ml/sec. To trap water from the breath 
samples a tube (8 cm, 4 mm ID) filled with CaCl2.2H2O was fitted in between the syringe and the 
Tenax tube. The end of the Tenax tube was extended with a 40 cm empty part that was coiled and 
sticking out of the dry ice. This acted as a gas reservoir for nitrogen gas that was passed over the 
Tenax after the samples (15 s at 200 ml/min). To desorb the trapped MT a three ml plastic syringe 
(Braun Injekt, fully polypropylene/ polyethylene, so no rubber plunger tip) was connected to the inlet 
of the Tenax tube which was subsequently taken out of the dry ice and quickly submerged completely 
in a hot water bath (95 °C). After 20 s in the water bath the three ml syringe was filled quickly in this 
way passing the hot nitrogen from the gas reservoir over the Tenax. The full content of the three ml 
syringe was now injected into the Agilent 7890B gas chromatograph (see above). The MT recovery of 
the Tenax trapping/desorbing method described here was about 60%. Calibration of MT for this 
method was done by injecting increasing amounts from a MT stock into a 15 L Tedlar bag that was 
filled with 10 L of clean air. The lower limit of detection for MT for this method was five ppt (parts 
per trillion). Loss of MT in Tedlar bags at room temperature was estimated at 10-25% after one day 
and verified for each bag used. Analysis was performed within 8 h (patient CII-2, loss < 10%) and 24 
h (patient AII-3, loss <10%), respectively. The Tenax trapping part of the method was similar to that 
described previously by Tangerman 58 who used liquid nitrogen for cooling. The method suffers from 
some inherent inaccuracies and difficulties. MT absorbs to the Teflon parts of the 100 ml glass 
syringe. The same syringe is used throughout and cleaning in between samples that can differ a factor 
of 30 in MT concentration is critical. The same is true for the Tedlar bags used for collecting breath 
samples. The variation in gas flow rate from the syringe when concentrating MT on the Tenax tube 
may cause differences in the Tenax zone (both width and position) that is loaded with MT and will 
influence the desorption behavior. Also the position of the Tenax tube in the dry ice pellets during 
loading and in the hot water bath for desorption of the Tenax tube has limited reproducibility, as has 
the gas flow rate during manual desorption of MT by the three ml syringe. Reproducibility of 
duplicate samples from the same bag was in general good with differences less than 20%. Only for the 
low ppt values close to detection level differences could be higher, up to 50%.  
 
Cell culture 
Fibroblasts were cultured using standard procedures in M199 medium (Gibco, Life Technologies) 
supplemented with 10% fetal calf serum (FCS, GE Healthcare, Diegem, Belgium), and 100 U/ml / 100 
µg/ml of penicillin/streptomycin (P/S) (Gibco) at 37 ºC with 5% CO2. All cell lines are routinely 
checked for mycoplasma infection and were only used in experiments when negative. 
 
Cell lysates and Western blot analysis 
For protein expression analysis by SDS-PAGE and Western blot analysis fibroblasts and colon cancer 
cell extracts were made by extraction in lysis buffer (50 mM Tris.HCl (pH 7.4), 150 mM NaCl, 1 mM 
EDTA, 10% glycerol, 1% Triton X-100) for 10 min. on ice and subsequent clearance (10 min., 13,000 
x g). Protein concentrations were measured using a Micro BCA protein assay kit (Thermo Scientific) 
using bovine serum albumin (BSA) as a standard. Forty µg of the total extracts were separated on 10 
% SDS-PAGE. Antisera used were: anti-V5 (#R960, Invitrogen monoclonal), anti-SELENBP1 
(#SAB2108611, Sigma affinity purified rabbit polyclonal), and anti-actin (#AC-15, Novus Biologicals 
mouse monoclonal). Western blot analysis was performed 2 -3 times for each experiment. 
Representative results are shown in the figures. For the MTO assay the snap frozen fibroblast and 
erythrocyte pellets that had been stored at -80 oC, were resuspended in PBS and homogenized by 
extensive pipetting. White blood cells were also resuspended in PBS and homogenized by 
sonification. The protein concentration of the resulting homogenates ranged from 1-4 mg/ml as 
measured with the Bio-Rad Protein Assay (Bio-Rad) using BSA as a standard. 
 
Tissue extracts 
Tissue samples (snap frozen and stored at -80 ºC) were thawed on ice, chopped finely, and homoge-
nized in Tris buffer using a tight fitting potter (10 mM Tris.HCl pH 7.4, 250 mM sucrose, 2 mM K+- 
EDTA, 5.104 U/l heparin). The homogenate was centrifuged (10 min, 600xg) and stored in aliquots at 
-80 ºC. 
 
Molecular genetic analysis 
Total DNA was extracted using the QIAamp DNA kit (Qiagen), and all exons and relevant splice sites 
were PCR amplified with primers containing the M13 forward or reverse sequence fused to a specific 
sequence and sequenced with M13 primers. Primer sequences are available upon request. Mutations 
were analyzed using Alamut version 2.5.1 with the integrated pathogenicity prediction tools. The 
Alamut splice site prediction module includes the following methods: SpliceSiteFinder-like, 
MaxEntScan, MNSplicer, GeneSplicer and Human Splicing Finder. Sequence alignment with 
SELENBP1 orthologues was done using the Clustal Omega (EMBL-EBI) webtool. 
For frequency analysis we used the Exome Aggregation Consortium (ExAC), Cambridge, MA (URL: 
http://exac.broadinstitute.org). We used the Combined Annotation-Dependent Depletion (CADD) tool 
to estimate the pathogenicity of mutations found in the ExAC browser. This tool prioritizes functional, 
deleterious, and pathogenic variants across many functional categories by using a CADD PHRED like 
C-score 59. 
 
Phylogenetic analysis of methanethiol oxidases and putative selenium-binding proteins 
The evolutionary history was inferred using the Neighbor-Joining method. The two enzymes with 
proven MTO activity are indicated in red. Accession numbers are given between parenthesis. The 
optimal tree with the sum of branch length = 10.21887791 is shown. The percentage of replicate trees 
in which the associated taxa clustered together in the bootstrap test (500 replicates) are shown next to 
the branches for values > 60. The tree is drawn to scale, with branch lengths in the same units as those 
of the evolutionary distances used to infer the phylogenetic tree. The evolutionary distances were 
computed using the Dayhoff matrix based method and are in the units of the number of amino acid 
substitutions per site. The analysis involved 45 amino acid sequences. All ambiguous positions were 
removed for each sequence pair. There were a total of 564 positions in the final dataset. Evolutionary 
analyses were conducted in MEGA6 52. 
 
SELENBP1 mRNA tissue expression analysis 
The expression profile of SELENBP1 was determined as described before 60. Primer sequences  
used to detect SELENBP1 mRNA expression levels can be found in Supplementary Table 2 . 
 
Structural analysis 
The structure of the heterologically expressed hypothetical selenium-binding protein from Sulfolobus 
tokodaii (st0059) was solved by X-ray crystallography and deposited in 2007 (PDB file 2ECE). This 
structure was used as a template to build a homology model of human SELENBP1 (40% identity).  
This model was used to study the structural details of the Gly225Trp and His329Tyr mutations and 
was created and visualized using the WHAT IF & YASARA Twinset 61,62. The figures were rendered 
with PovRay (http://www.povray.org/). 
 
Lentiviral complementation 
A gateway compatible expression vector for wild type SELENBP1 without a stop codon was 
purchased from PlasmID/ Harvard Medical School and recombined with the pLenti6.2V5-DEST 
destination vector (Invitrogen) using the Gateway LR Clonase II Enzyme Mix (Invitrogen) according 
to the manufacturer’s instructions. The resulting pLenti6.2-SELENBP1-V5 or the control construct 
pLenti6.2-AcGFP-V5 (Aequorea coerulescens Green Fluorescent Protein) were used to produce 
viruses for fibroblast infection and selection of stable expressing cells as was described 63.  
 
Immunofluorescent microscopy 
For immunofluorescent detection of V5-tagged SELENBP1 the stably transduced patient fibroblasts 
were grown on coverslips. The cells were fixed using 3.3% paraformaldehyde in cell culture medium 
for 15 min., washed three times with PBS and permeabilized for 15 min. with 0,5 Triton X-100 in 
PBS/10% FCS. The primary antibody (anti-V5) was diluted 1:100 in PBS/10% FCS and incubated for 
one hour. After extensive washing the secondary antibody (goat-anti-mouse IgG AlexaFluor 568, 
Invitrogen) was diluted 1:1000 in PBS/10% FCS and incubated for one hour. After washing the slides 
were mounted using ProLong® Gold antifade with DAPI (Invitrogen). Image acquisition was 
performed using a Zeiss Observer Z1with LED illumination and appropriate emission filters. 
 
MTO enzyme assay 
MTO enzymatic activity was measured by incubating cell homogenates or plasma in closed bottles 
and measuring the disappearance of added MT via headspace GC analysis. The use of new glassware 
proved essential for obtaining low and reproducible background measurements. To compare MTO 
activity in fibroblast- and colon cell lines, we used three ml Exetainer vials (Labco Limited). Cell 
homogenates (400-700 µl, equivalent to 0.75 - 1.85 mg of protein) were transferred in the vials and 
ZnSO4 (0.2 mM final concentration) was added to trap H2S produced by MTO. This concentration was 
found not to inhibit the MTO enzymatic activity. After closing the bottles 12-25 µl of a freshly 
prepared MT stock solution (0.82 mM) was added by syringe, resulting in a MT concentration in the 
liquid phase of 12-23 µM. Vials were horizontally shaken at 200 rpm and 35 ºC. For MT analysis 100 
µl gas samples were taken by syringe and determined by GC analysis. Because of the reactivity of 
MT, mainly oxidation into dimethyldisulfide, we always detected low levels of MT disappearance in 
control bottles without added enzyme. These rates were subtracted from experimental rates. For MTO 
activity measurements in erythrocytes and mouse tissue extracts the standard assay was performed in 
250 ml screw cap serum bottles (neck size 28 mm ID). This allowed bigger gas samples to be taken for 
GC analysis with less effects of changing the gas volume and septum leakage. Also background MT 
disappearance was much lower. Bottles with 25 ml of PBS containing ZnSO4 (0.2 mM) and BSA 
(0.3mg/ml) were closed with red rubber septa and incubated at 350 rpm at 35 ºC. Four nmoles of MT 
were added, resulting in about 50 nM in the liquid phase. For the determination of the reaction 
stoichiometry and the oxygen dependency higher MT concentrations were used (20 - 75 nmoles, 
giving 250-950 nM MT in the liquid). After preincubation with MT for 15 - 20 min. the MTO reaction 
was started by the addition of erythrocytes or tissue extracts which were diluted in 1 ml PBS. Gas 
samples (1 ml) were taken every 1.5 - 4 min. for GC analysis. The lower limit of detection for MTO 
activity in erythrocytes was 0.01 nmol.µl-1.h-1, in fibroblasts 0.5 nmol.mg protein-1.h-1 and in mouse 
tissue extracts 1 nmol.mg protein-1.h-1. To study the kinetics of MTO in erythrocytes and colon cells 
the assay was scaled up to 500 ml serum bottles with 50 ml PBS. The amount of MTO added was 
adjusted in a way to obtain a reliable MT consumption rate over a period of about 10 -20 min. 
At the end of the incubations with fibroblasts Zn-trapped H2S was released by the addition HCl to a 
final concentration of 0.1M using a syringe and shaking the bottles for ten min. at 25 ºC to reach gas-
liquid equilibration for H2S. The resulting H2S concentration was determined in the headspace by GC 
analysis. Total H2S was calculated by assuming a gas/liquid concentration ratio for H2S of 1 : 2.47 
which was calculated from reported solubility data 64. Addition of Zn traps the H2S that otherwise 
builds up in time and inhibits the MTO enzyme reaction. 
The gas/liquid ratio for the concentration of MT in PBS at 35 ºC was determined at 1: 5.5. This was 
calculated from the amount of MT that dissolved in the liquid after addition of a fixed amount of MT 
to a closed 50 ml bottle that contained 10 ml of PBS. The dissolved amount was determined by 
comparing the headspace MT concentration of the gas phase in this bottle with the gas phase MT 
concentration in an empty bottle (so without PBS) that received the same amount of MT. A slightly 
different ratio of 1:5 was obtained when using PBS in 250 ml bottles to which also BSA (0.3 mg.ml-1) 
was added. For sulfide a gas/liquid ratio of 1: 12.5 was obtained in such bottles. After acidification a 
value of 1: 5.5 was found and this is much lower than expected at 35 ºC (1:2) 64. We attributed the 
higher amount of sulfide dissolved to the presence of BSA for which adsorption of sulfide has been 
suggested 65. 
The BRENDA database was accessed at: http://www.brenda-enzymes.org/. 
To determine DMS in mouse plasma 200 µl samples were introduced via a septum into a closed glass 
syringe with 3 ml of air that was preincubated at 70 oC in a waterbath and incubated for another 5 
minutes with intermittent shaking. At 70 oC most of the DMS from the sample is in the gas phase. 2.6 
ml of gas phase was transferred into a 3 ml syringe and analyzed by GC. From water samples with 
DMS, >80% was recovered in this way. The DMS lower limit of detection was 1.5 nM. 
 DATA AVAILABILITY  
Data that support the findings of this study are available from the corresponding author upon 
reasonable request.  
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